We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why You Should Retain IQVIA Holdings (IQV) Stock for Now
Read MoreHide Full Article
IQVIA Holdings Inc.’s (IQV - Free Report) shares have gained 8.3% in the past month, outperforming the 3.8% rise of the Zacks S&P 500 composite.
IQV has an impressive Growth Score of B. This style score condenses all the essential metrics from the company’s financial statements to get a true sense of the quality and sustainability of its growth. It has a long-term (three to five years) expected EPS growth rate of 10.7%.
IQVIA’s enormous treasure trove of information is a distinguishing asset and also perhaps a big barrier to entry for competitors. It has a huge collection of healthcare information that encompasses more than one billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics, and social media.
The company’s burgeoning information set contains around 60 petabytes of proprietary data sourced from around 150,000 data suppliers and covers more than one million data feeds globally. It delivers information and insights on roughly 85% of the world’s pharmaceuticals. IQVIA’s unique ability to standardize, organize and integrate this information through applying sophisticated analytics and global technology infrastructure helps it to build a strong client base. In 2022, the company added 275 more customers to its tally.
IQVIA has a consistent record of share repurchases. In 2022, 2021 and 2020, the company repurchased shares worth $1.17 billion, $406 million and $447 million, respectively. Such moves not only instill investors’ confidence but also positively impact earnings per share.
Some Risks
IQVIA’s current ratio at the end of first-quarter 2023 was pegged at 0.8, lower than the current ratio of 0.93 reported at the end of the prior-year quarter. A decline in the current ratio is not desirable as it indicates that the company may have problems meeting its short-term obligations.
Zacks Rank and Stocks to Consider
IQV currently carries a Zacks Rank #3 (Hold).
Investors interested in the Zacks Business Services sector can consider the following better-ranked stocks.
The company has an impressive earning surprise history, beating the consensus mark in all the trailing four quarters. The company has an average surprise of 37.3%.
Maximus (MMS - Free Report) : MMS carries a Zacks Rank of 2 and has a VGM score of A.
The company has an impressive earning surprise history, beating the Zacks Consensus mark in three instances and missing once, the average surprise being 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why You Should Retain IQVIA Holdings (IQV) Stock for Now
IQVIA Holdings Inc.’s (IQV - Free Report) shares have gained 8.3% in the past month, outperforming the 3.8% rise of the Zacks S&P 500 composite.
IQV has an impressive Growth Score of B. This style score condenses all the essential metrics from the company’s financial statements to get a true sense of the quality and sustainability of its growth. It has a long-term (three to five years) expected EPS growth rate of 10.7%.
IQVIA Holdings Inc. Price
IQVIA Holdings Inc. price | IQVIA Holdings Inc. Quote
Factors That Bode Well
IQVIA’s enormous treasure trove of information is a distinguishing asset and also perhaps a big barrier to entry for competitors. It has a huge collection of healthcare information that encompasses more than one billion comprehensive, longitudinal, non-identified patient records across sales, prescription and promotional data, electronic medical records, medical claims, genomics, and social media.
The company’s burgeoning information set contains around 60 petabytes of proprietary data sourced from around 150,000 data suppliers and covers more than one million data feeds globally. It delivers information and insights on roughly 85% of the world’s pharmaceuticals. IQVIA’s unique ability to standardize, organize and integrate this information through applying sophisticated analytics and global technology infrastructure helps it to build a strong client base. In 2022, the company added 275 more customers to its tally.
IQVIA has a consistent record of share repurchases. In 2022, 2021 and 2020, the company repurchased shares worth $1.17 billion, $406 million and $447 million, respectively. Such moves not only instill investors’ confidence but also positively impact earnings per share.
Some Risks
IQVIA’s current ratio at the end of first-quarter 2023 was pegged at 0.8, lower than the current ratio of 0.93 reported at the end of the prior-year quarter. A decline in the current ratio is not desirable as it indicates that the company may have problems meeting its short-term obligations.
Zacks Rank and Stocks to Consider
IQV currently carries a Zacks Rank #3 (Hold).
Investors interested in the Zacks Business Services sector can consider the following better-ranked stocks.
Green Dot (GDOT - Free Report) : GDOT currently carries a Zacks Rank #2 (Buy) and has a VGM score of A. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The company has an impressive earning surprise history, beating the consensus mark in all the trailing four quarters. The company has an average surprise of 37.3%.
Maximus (MMS - Free Report) : MMS carries a Zacks Rank of 2 and has a VGM score of A.
The company has an impressive earning surprise history, beating the Zacks Consensus mark in three instances and missing once, the average surprise being 9.6%.